ACLF/SACLF, compensated liver cirrhosis, decompensated liver cirrhosis
Conditions
Interventions
Liver failure:NA
Decompensated liver cirrhosis:NA
Compensated liver cirrhosis:NA
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 75 years old, regardless of gender. 2. Patients with liver failure: Meet either item 1 or item 2. 1)ACLF: Serum total bilirubin >= 5 mg/dL (85 µmol/L) and coagulation dysfunction (INR >= 1.5) occur within 4 weeks on the basis of chronic liver disease. 2)SACLF: Serum total bilirubin >= 5 mg/dL (85 µmol/L) and coagulation dysfunction (INR >= 1.5) occur within 4 to 24 weeks on the basis of chronic liver disease. 3. Patients with decompensated liver cirrhosis: Meet either item 1 or item 2, and item 3 is a necessary condition. 1) Abdominal color Doppler ultrasound/Abdominal CT/Abdominal MRI suggests liver cirrhosis. 2) Fibroscan (F >= 12.4 Kpa) or the histological fibrosis score of the liver is above F4 (Ishak scoring system). 3) Complications related to decompensation occur: ascites/rupture and bleeding of esophagogastric varices/hepatic encephalopathy. 4.Patients with compensated liver cirrhosis: Meet either item 1 or item 2, and item 3 is a necessary condition. 1) Abdominal color Doppler ultrasound/Abdominal CT/Abdominal MRI suggests liver cirrhosis. 2) Fibroscan (F >= 12.4 Kpa) or the liver histology is above F4 (Ishak scoring system). 3) There are no complications related to decompensation: ascites/rupture and bleeding of esophagogastric varices/hepatic encephalopathy.
Exclusion criteria
Exclusion criteria: 1. Acute liver failure; 2. After Transjugular Intrahepatic Portosystemic Shunt (TIPS) surgery; 3. Combined with severe insufficiency of cardiac, pulmonary and renal functions or malignant tumor; 4. Combined with HIV infection; 5. Pregnancy or lactation period; 6. Iodine allergy; 7. Allergic constitution; 8. Hypoxemia that cannot be corrected; 9. Unstable vital signs; 10. Active gastrointestinal bleeding; 11. Inability to cooperate quietly with the examination; 12. The researcher deems it inappropriate to be included in the study;
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Tumor marker;Blood routine test;Biochemical indicators;Coagulation routine test;Imaging indicators;Virological indicators; | — |
Primary
| Measure | Time frame |
|---|---|
| Survival prognosis of the patient / Liver transplantation;Hepatic reserve function; | — |
Countries
China
Contacts
Public ContactHong Tang
West China Hospital of Sichuan University
Outcome results
None listed